Dry Eye News and Research

RSS

Dry eye is one of the most common complaints seen by eye doctors, accounting for nearly one fourth of all office visits. Caused by insufficient tear production or excessive tear evaporation, dry eye can be a mild, episodic feeling of discomfort associated with certain circumstances, such as exposure to dry, hot or windy environments; however, it can also be a chronic medical condition that, if left untreated, may lead to increased risk of infection or visual impairment.

FDA approves Abbott's CREON sNDA including dosing guidance for treating EPI due to CP, pancreatectomy

Abbott announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for CREON® (pancrelipase) Delayed-Release Capsules that now includes dosing guidance in the prescribing information specific to patients with limited production of enzymes in the pancreas (exocrine pancreatic insufficiency) due to chronic pancreatitis (CP) or removal of the pancreas (pancreatectomy). Prior to this FDA approval, dosing guidance for medications such as CREON was based on patients with cystic fibrosis.

3 May 2010

Valeant Pharmaceuticals International reports 30% increase in total revenue for first-quarter 2010

Valeant Pharmaceuticals International today announced first quarter financial results for 2010.

3 May 2010

SARcode presents positive results from Phase 2 study of SAR 1118 ophthalmic solution at Dry Eye Summit

SARcode Corporation, a privately-held biotechnology company focused on developing a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists, today announced results of a 230 patient Phase 2 proof-of-concept study evaluating topical SAR 1118 ophthalmic solution in the treatment of aqueous deficient dry eye (keratoconjunctivitis sicca).

3 May 2010

PolyTouch Medical files Premarket 510(k) application for PatchAssist laparoscopic mesh deployment device

PolyTouch Medical Ltd., a leading developer of laparoscopic hernia mesh placement technologies, today announced that it has filed a Premarket 510(k) Application with the US Food and Drug Administration for PatchAssist, an Innovative Laparoscopic Mesh Deployment and Placement Device that enables accurate mesh placement in laparoscopic ventral hernia repair potentially reducing procedure time by 30%-50%.

3 May 2010

Stimatix reports interim results from artificial sphincter trial for restoring bowel control in people with stoma

Stimatix GI, located in the Misgav Venture Accelerator, has reported encouraging interim results in its animal trials of the AOS-C1000 artificial sphincter, designed to provide stoma patients with a new means of bowel control.

3 May 2010

Inspire Pharmaceuticals reports net loss of $14.8M for first-quarter 2010

Inspire Pharmaceuticals, Inc. announced today financial results for the first quarter ended March 31, 2010, reporting a net loss of $14.8 million or ($0.18) per share.

3 May 2010

ISTA Pharmaceuticals first-quarter net revenues up 39%

ISTA Pharmaceuticals, Inc., today reported financial results for the quarter ended March 31, 2010. First quarter 2010 net revenues were $28.3 million, an increase of 39% from the first quarter of 2009. Net income for the first quarter ended March 31, 2010, was $0.5 million, or $0.01 per share, compared to a net loss of $19.6 million, or $0.59 per share, for the first quarter ended March 31, 2009.

30 Apr 2010

IP Advocate founder settles long-standing legal battle with UGARF

In a move that positions IP Advocate for its next chapter as a champion of research translation, founder Dr. Renee Kaswan today announced that she has settled her long-standing legal battle with the University of Georgia Research Foundation.

21 Apr 2010

Japanese ministry approves DIQUAS Ophthalmic Solution 3% for dry eye treatment

Santen Pharmaceutical Co., Ltd. and Inspire Pharmaceuticals, Inc. announced today that the Japanese Ministry of Health, Labour and Welfare granted approval for the new dry eye treatment drug, DIQUAS Ophthalmic Solution 3% (generic name: diquafosol tetrasodium), on April 16, 2010.

From Santen Pharmaceutical Co., Ltd. 17 Apr 2010

RegeneRx Biopharmaceuticals proposes common stock public offering

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration in cardiovascular diseases, central nervous system injuries, ophthalmic indications and dermal wounds, announced today that it intends to offer units consisting of shares of its common stock and warrants to purchase shares of its common stock in a public offering.

17 Apr 2010

Omega-3 fatty acids improve nerve regeneration, prevent psychotic disorders and reduce cellular aging

Improving nerve regeneration after corneal surgery, preventing psychotic disorders in those at high risk for them and reducing cellular aging are three emerging benefits of the omega-3 fatty acids found in seafood, according to milestone research described in the April 2010 PUFA Newsletter and Fats of Life online publications for health professionals and consumers, respectively.

9 Apr 2010

Biosense Webster obtains first Ethics Committee approval for CLARITY study

Biosense Webster announces that this week it has obtained its first Ethics Committee approval for the CLARITY study, comparing the 1-year efficacy, safety and efficiency of CARTO(R) 3 System-guided radiofrequency ablation using the NAVISTAR(R) THERMOCOOL(R) Catheter versus fluoroscopy-guided radiofrequency ablation using the Pulmonary Vein Ablation Catheter(R) (PVAC(R), Ablation Frontiers, Medtronic) in patients with paroxysmal atrial fibrillation.

9 Apr 2010

Cell Therapeutics receives FDA Complete Response Letter for Pixuvri NDA

Cell Therapeutics, Inc. today announced that it had received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for Pixuvri™ (pixantrone dimaleate) for relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL").

9 Apr 2010

Dry-mouth and dry-eye symptoms often misdiagnosed by healthcare professionals

Results from a recent survey of 400 Sjogren's syndrome patients showed that half of those surveyed experienced common symptoms such as dry mouth or dry eyes for three or more years before receiving an accurate diagnosis from a healthcare professional.

6 Apr 2010

Alcon acquires right to market DUREZOL ophthalmic corticosteroid in U.S.

Alcon, the world's leader in eye care, announced today that it received regulatory approval and finalized the acquisition of the rights in the United States for DUREZOL™ emulsion and the global rights, excluding Latin America, for ZYCLORIN™ from Sirion Therapeutics, Inc.

30 Mar 2010

Isotechnika Pharma releases fourth quarter financial results; reviews operational and scientific highlights for 2009

Isotechnika Pharma Inc. has released its financial results for the fourth quarter and year ended December 31, 2009 and provided a review of the Company's operational and scientific highlights for 2009

25 Mar 2010

Special medicated contact lenses can help treat common eye disorders

The popular dietary supplement vitamin E, loaded into special medicated contact lenses, can keep glaucoma medicine near the eye - where it can treat that common disease- almost 100 times longer than possible with current commercial lenses, scientists reported here today.

25 Mar 2010

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

Can-Fite BioPharma Ltd, a biopharmaceutical company, traded on the TASE and developing anti- inflammatory and anti-cancer drugs, announced today the filing of a patent application, in conjunction with the United Stated National Institutes of Health (NIH), for the treatment of Uveitis with its A3 adenosine receptor ligands.

23 Mar 2010

Academic Inventors’ Bill of Rights unveiled in poster presentation at AUTM Annual Meeting

As technology transfer managers from around the country prepare today to debate the role of academic researchers in commercializing their own inventions, two experts – one from each side of the aisle – have come together to propose an Academic Inventors’ Bill of Rights.

18 Mar 2010

Acucela, Otsuka Pharmaceutical granted FDA Fast Track designation for ACU-4429 in treatment of dry AMD

Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, and Otsuka Pharmaceutical Co., Ltd., today announced that they have received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ACU-4429, an investigational oral treatment for dry age-related macular degeneration (dry AMD).

17 Mar 2010

Dry Eye News and Research

Further Reading

FDA approves Abbott's CREON sNDA including dosing guidance for treating EPI due to CP, pancreatectomy

Valeant Pharmaceuticals International reports 30% increase in total revenue for first-quarter 2010

SARcode presents positive results from Phase 2 study of SAR 1118 ophthalmic solution at Dry Eye Summit

PolyTouch Medical files Premarket 510(k) application for PatchAssist laparoscopic mesh deployment device

Stimatix reports interim results from artificial sphincter trial for restoring bowel control in people with stoma

Inspire Pharmaceuticals reports net loss of $14.8M for first-quarter 2010

ISTA Pharmaceuticals first-quarter net revenues up 39%

IP Advocate founder settles long-standing legal battle with UGARF

Japanese ministry approves DIQUAS Ophthalmic Solution 3% for dry eye treatment

RegeneRx Biopharmaceuticals proposes common stock public offering

Omega-3 fatty acids improve nerve regeneration, prevent psychotic disorders and reduce cellular aging

Biosense Webster obtains first Ethics Committee approval for CLARITY study

Cell Therapeutics receives FDA Complete Response Letter for Pixuvri NDA

Dry-mouth and dry-eye symptoms often misdiagnosed by healthcare professionals

Alcon acquires right to market DUREZOL ophthalmic corticosteroid in U.S.

Isotechnika Pharma releases fourth quarter financial results; reviews operational and scientific highlights for 2009

Special medicated contact lenses can help treat common eye disorders

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

Academic Inventors’ Bill of Rights unveiled in poster presentation at AUTM Annual Meeting

Acucela, Otsuka Pharmaceutical granted FDA Fast Track designation for ACU-4429 in treatment of dry AMD

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News